Loading
Latest filing published 03 Jun 2022 for INVO Bioscience, Inc., €8,213.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Jeffrey Segal (board member) discloses dealings in INVO Fertility, Inc. to SEC (Form 4). We count 4 filings; the first trade dates from 27 November 2020 and the latest from 1 June 2022.
No open-market sale appears; the market trades are 1 purchase worth €8,213. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 3 share grants. So far in 2022, the count stands at 1 purchase and no sales.
The newest entry dates from 3 June 2022: an open-market purchase of €8,213, in INVO Fertility, Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
2 of 2 declarations